Brief: Morphosys Reports Q4 Group Revenue At EUR 59.0 Mln, Down 28%

Morphosys AG

13/03/2024 20:01

March 13 (Reuters) - MorphoSys AG  MORG.DE :
    * MORPHOSYS AG -  AGREEMENT TO BE ACQUIRED BY NOVARTIS FOR
EUR
68.00 PER SHARE IN CASH OR EUR 2.7 BILLION EQUITY VALUE
    * MORPHOSYS AG - Q4 OPERATING LOSS OF EUR 81.4 MILLION
VERSUS EUR
68.4 MILLION IN Q4 2022
    * MORPHOSYS AG - FY GROUP REVENUE AT EUR 238.3 MILLION, DOWN
14%
YEAR-ON-YEAR
    * MORPHOSYS AG - Q4 GROUP LOSS AT EUR 48.3 MILLION VERSUS
EUR
329.4 MILLION IN Q4 2022
    * MORPHOSYS AG - FY OPERATING LOSS AT EUR 252.5 MILLION
VERSUS EUR
220.7 MILLION YEAR AGO
    * MORPHOSYS AG - Q4 GROUP REVENUE AT EUR 59.0 MILLION, DOWN
28%
YEAR-ON-YEAR
    * MORPHOSYS AG - FY GROUP LOSS AT EUR 189.7 MILLION VERSUS
EUR
151.1 MILLION YEAR AGO
    * MORPHOSYS AG -  UNTIL FURTHER NOTICE, MORPHOSYS TO NO
LONGER
PROVIDE A FORECAST FOR REVENUES FROM PRODUCT SALES, AS NO SUCH
REVENUES WILL BE REALISED
    * MORPHOSYS AG - OUTLOOK 2024: MARKETING AUTHORISATION
APPLICATION
TO THE EUROPEAN MEDICINES AGENCY IN MID-2024
    * MORPHOSYS AG - OUTLOOK 2024:  SUBMISSION OF A NEW DRUG
APPLICATION (NDA) FOR PELABRESIB IN COMBINATION WITH RUXOLITINIB
IN MYELOFIBROSIS TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
    * MORPHOSYS AG - ANY EFFECTS FROM THE IMPLEMENTATION OF THE
NOVARTIS TAKEOVER OFFER ARE NOT INCLUDED IN THIS FORECAST

Source text for Eikon:  ID: 
Further company coverage:  MORG.DE 

 ((Reuters.Briefs@thomsonreuters.com;))